The impact of a diabetes care team on the glycaemic control of paediatric and adolescent patients with type 1 diabetes mellitus at Tygerberg Children’s Hospital

Z Kajee,1 MB ChB, FCPaed (SA), MMed (Paeds), Cert Neonatology; J Harvey,2 MCom, PhD; E W Zöllner,1 MB ChB, DCH, DTM&H, DPH, MMed (Paeds), PhD (Paeds)

1 Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Tygerberg Hospital and Stellenbosch University, Cape Town, South Africa
2 Department of Statistics and Actuarial Science, Faculty of Economics and Management Sciences, Stellenbosch University, Stellenbosch, South Africa

Corresponding author: E W Zöllner (zollner@sun.ac.za)

Background. A diabetes care team (DCT) may contribute to improved glycaemic control in type 1 diabetes mellitus (T1DM) patients. Hence a DCT was introduced at Tygerberg Children’s Hospital (TCH) in 2009.

Hypothesis. A DCT for T1DM patients improves HbA1c, reduces admission and diabetic ketoacidosis (DKA) rates and insulin dose, and decreases the prevalence of complications.

Methods. In this retrospective cohort study, records of 190 T1DM patients attending the paediatric diabetic clinic at TCH between August 2004 and July 2011 were reviewed. Data extracted include: glycated haemoglobin (HbA1c) levels; total number of admissions; DKA and recurrent DKA (rDKA) admissions; insulin regimen and dose; and presence of complications. Four periods, in which specific changes to team composition occurred, were compared.

Results. HbA1c levels increased from 9.0% (7.85 - 10.15) in P1 to 10.9% (9.6 - 12.2) in P2, but decreased to 9.3% (8.75 - 9.75) in P4 (p=0.02). The mean insulin dose decreased from 1.19 (1.08 - 1.31) to 0.93 (0.87 - 1.00) units/kg/day (p<0.01). The number of admissions decreased from 0.79 (0.46 - 1.12) to 0.18 (0.02 - 0.34) (p<0.01). The DKA rate decreased from 32.5/100 patient years to 23.5/100 patient years. The rDKA rate decreased from 18.8% in P1 to 9.6% in P4. Daily insulin injections increased from 2.97 (2.85 - 3.01) to 3.06 (3.06 - 3.23) (p=0.01). The mean insulin dose decreased from 1.19 (1.08 - 1.31) to 0.93 (0.87 - 1.00) units/kg/day (p=0.00). The number of admissions decreased from 0.79 (0.46 - 1.12) to 0.18 (0.02 - 0.34) (p<0.01). The DKA rate decreased from 32.5/100 patient years to 23.5/100 patient years. The rDKA rate decreased from 18.8% in P1 to 9.6% in P4. Daily insulin injections increased from 2.97 (2.85 - 3.01) to 3.06 (3.06 - 3.23) (p=0.01). The mean insulin dose decreased from 1.19 (1.08 - 1.31) to 0.93 (0.87 - 1.00) units/kg/day (p=0.00).

Conclusion. After the introduction of the DCT, HbA1c levels were less variable and hospital admission and DKA rates decreased. Improvements were achieved with a multiple injection regimen at a lower daily insulin dose.

Type 1 diabetes mellitus (T1DM) is among the most frequent chronic non-infectious diseases in children.1 There appears to be a worldwide increase in T1DM in children and adolescents.2 The incidence of T1DM is currently estimated at 5 new cases per 100 000 in the Western Cape, South Africa (SA), compared to 2 - 35 new cases per 100 000 worldwide.3

Once a patient has been diagnosed with T1DM, it is important to gain adequate metabolic control to delay the onset and limit the progression of complications resulting from the disease.4 To this end, the International Society for Pediatric and Adolescent Diabetes (ISPAD) recommends that a multidisciplinary diabetes care team (DCT) should be established, consisting of a diabetes specialist, a diabetes nurse educator (DNE), a dietitian and a social worker.5,6

Including a DNE in the team has been shown to be effective in reducing the error rate in blood glucose measurements7 and the duration of hospitalisation in both children and adults.8,9 In adult type 2 diabetes patients, marked improvements in glycated haemoglobin (HbA1c) levels have been observed after a DNE had participated in their routine diabetes care.8,9 This result is supported by findings that showed a primary nurse practitioner succeeding in implementing the recommendations of the Diabetes Control and Complications Trial (DCCT) in paediatric diabetes patients within 1 year, resulting in a significant decrease in HbA1c.10 It has further been shown that a DNE’s regular telephone contact with poorly controlled T1DM patients had a delayed rather than an immediate beneficial effect.11 A direct link between HbA1c levels and the number of visits to a DCT per year has been shown in the paediatric population.12

In adult T1DM patients, onset of complications was delayed when specialist care was maintained after childhood13 and a decrease in retinopathy and microalbuminuria has been demonstrated in adolescent patients irrespective of better glycaemic control.14,15 The impact of management by a DNE or DCT on hospital admission and diabetic ketoacidosis (DKA) rates, especially in the paediatric age group, seems to be poorly documented.

Tygerberg Children’s Hospital (TCH) introduced a DCT consisting of a paediatric endocrinologist, a dietitian and a social worker in August 2007. Owing to financial constraints, a DNE could be appointed only in August 2009. It was hypothesised that the introduction of a full DCT for children and adolescents with T1DM at TCH would improve patients’ HbA1c levels, reduce hospital admission and DKA rates, and decrease the prevalence of complications.

Methods

Study design

This was a retrospective cohort study (with cross-sectional elements) of 190 T1DM children and adolescents attending the paediatric diabetes clinic at TCH, Cape Town, from August 2004 to July 2011. Participants were included if:

• they required insulin therapy after the neonatal period but before adolescence, irrespective of whether T1DM was confirmed on low serum C-peptide levels and elevated antiglutamic acid decarboxylase/islet antigen 2 antibodies
• they were managed during the following periods:
  August 2004 - July 2005 (P1) – only a paediatric endocrinologist on site
  August 2007 - July 2008 (P2) – introduction of the DCT
  August 2009 - July 2010 (P3) – DNE included in the team
  September 2010 - July 2011 (P4) – DNE changed.

Patients with type 2, neonatal or monogenic diabetes were excluded from the study.

The diabetes care team

The paediatric endocrinologist, registrar and intern were primarily responsible for the medical care of each patient, while the DNE educated the patients about diabetes and trained them in the necessary skills for managing the condition. The diettian provided dietetic input. The social worker intervened whenever social or behavioural issues were identified. Patients were seen at least 4 times per year.

Data collection

The hospital records of the identified patients were reviewed to capture the following data: age; sex; age at diagnosis; ethnicity; types of insulin; number of injections per day; insulin dose; mean HbA1c level at the end of each period; hospital admissions due to DKA or poor control; prevalence of DKA and recurrent DKA (rDKA); mean urine albumin–creatinine ratio (UAC) at the end of each period; presence of retinopathy, neuropathy and limited joint mobility (LJM); fasting total serum cholesterol; low-density lipoprotein (LDL) cholesterol; high-density lipoprotein (HDL) cholesterol; and triglycerides. The cholesterol and triglyceride levels were categorised as high or normal according to Mayo Clinic criteria.[21]

Complication assessment was performed annually, starting 5 years after onset of T1DM in prepubertal patients and 2 years after onset of T1DM in pubertal patients. Microalbuminuria was defined by a UAC level ≥2 mg/mmol in two early-morning urine samples (taken at consecutive clinic visits). Retinopathy was initially confirmed visually by an ophthalmologist, but replaced by fundal photography from P4. Neuropathy was initially tested for by assessing pain and touch sensation. Vibration sense testing was introduced late in P3. LJM was determined qualitatively according to the prayer manoeuvre.

Glycated haemoglobin measurements

Before 2009, HbA1c levels were measured by the local laboratory using an assay standardised to the DCCT assay and certified by the National Glycohemoglobin Standardization Program. From 2009, HbA1c levels were analysed with the DCA Vantage Analyzer point-of-care device (Siemens, USA). The results of the two methods were compared in 35 subjects. The within-assay coefficient of variation (CV) was 1.2% for an HbA1c level of 5.1% and 4.3% for an HbA1c level of 12.9%. The between-assay CV was 2.4% and 3.2% for the two reference levels, respectively (personal communication from MA van Rensburg).

Statistical analysis

Data were collated in a spreadsheet and analysed using Statistica version 12 (Dell, USA). Continuous data were analysed descriptively using means and standard deviations with 95% confidence intervals (CIs) to estimate the true population mean. Frequency distributions were used to describe ordinal and nominal data. A significance level of p<0.05 was applied throughout.

The primary objective was to compare variables between the four treatment periods. As the same patient was observed in more than one period, the observations between periods for a particular patient are dependent. The Friedman analysis of variance (ANOVA) was therefore used to compare changes between the different periods. However, owing to missing data, recruitment over time and patient dropout, there were only a few patients who had observations in all four periods for all variables. Combinations of the periods were therefore tested. Periods P1, P2 and P3 were compared using Friedman’s ANOVA, as were P2, P3 and P4. Box-and-whisker plots were used to illustrate these comparisons graphically.

For all other comparisons of continuous variables between two groups, the Mann–Whitney U test was used, and for more than two groups the Kruskal–Wallis ANOVA was applied. Comparison of two nominal variables was performed using a chi-square test and a Fisher’s exact test for the 2x2 contingency tables. HbA1c levels were compared against sex and LJM (including the interaction) using multiple regression (this comparison was necessary because of a sex difference in the prevalence of LJM).

Ethical approval

Ethical approval was obtained from the Health Research Ethics Committee at Stellenbosch University (ref. no. N11/09/273).

Results

The records of 190 paediatric and adolescent T1DM patients were assessed over the four periods. In each period, new patients were diagnosed, others were lost to follow-up and some were transferred to the adult service. Not every patient was seen during every period, resulting in varying patient numbers per period. Patient numbers increased cumulatively over time: we saw 77 patients in P1 and 139 patients in P4. Ethnic or gender composition of the sample (Table 1) did not affect the outcome of the statistical analysis, except with regard to LJM, found in 60% (95% CI 43.3 - 75.1) of boys and 37.5% (95% CI 26.4 - 50.0) of girls (p=0.0291). This difference was not related to worse glycaemic control in boys.

Table 1. Patient characteristics at study entry (N=190)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (years)*</td>
<td></td>
</tr>
<tr>
<td>&lt;2</td>
<td>15 (8)</td>
</tr>
<tr>
<td>2 - 10</td>
<td>88 (46.3)</td>
</tr>
<tr>
<td>≥10</td>
<td>86 (45)</td>
</tr>
<tr>
<td>Age category organised according to gender (years)*</td>
<td></td>
</tr>
<tr>
<td>Boys &lt;12</td>
<td>49 (25.8)</td>
</tr>
<tr>
<td>Boys ≥12</td>
<td>17 (8.9)</td>
</tr>
<tr>
<td>Girls &lt;11</td>
<td>88 (46.3)</td>
</tr>
<tr>
<td>Girls ≥11</td>
<td>35 (18.4)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>66 (34.7)</td>
</tr>
<tr>
<td>Female</td>
<td>124 (65.3)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>Mixed ancestry</td>
<td>143 (75.3)</td>
</tr>
<tr>
<td>Black</td>
<td>25 (13.2)</td>
</tr>
<tr>
<td>White</td>
<td>22 (11.6)</td>
</tr>
<tr>
<td>Types of insulin therapy*</td>
<td></td>
</tr>
<tr>
<td>Short-acting</td>
<td></td>
</tr>
<tr>
<td>Human soluble insulin</td>
<td>164 (86.8)</td>
</tr>
<tr>
<td>Rapid-acting insulin analogue</td>
<td>25 (13.2)</td>
</tr>
<tr>
<td>Longer-acting</td>
<td></td>
</tr>
<tr>
<td>NPH† insulin</td>
<td>181 (95.3)</td>
</tr>
<tr>
<td>Long-acting insulin analogue</td>
<td>9 (4.7)</td>
</tr>
</tbody>
</table>

*Data missing in one patient.
†Neutral protamine Hagedorn.
Glycaemic control
The mean HbA1c level across all patients was 9.9% (95% CI 9.1 - 10.8) in P1, 11.7% (95% CI 10.9 - 12.6) in P2, 10.2% (95% CI 9.8 - 10.5) in P3 and 9.8% (95% CI 9.4 - 10.1) in P4 (Fig. 1). Only 22 patients had HbA1c data in all four periods. Their mean HbA1c levels followed a similar pattern over time, but were significantly different ($p=0.02$).

Number of hospital admissions
The number of admissions of the 34 patients seen in all four periods decreased progressively ($p=0.01$) (Fig. 2). Some were not admitted at all during a period, thereby reducing the mean number of admissions to <1.

Diabetic ketoacidosis and recurrent diabetic ketoacidosis
The DKA rate improved progressively over the four periods, from 32.5/100 patient years in P1 to 23.5/100 patient years in P4. A similar pattern was observed for the rDKA rate, which decreased from 18.8% in P1 to 9.6% in P4. More girls presented with rDKA.

Insulin therapy
Human soluble and neutral protamine Hagedorn (NPH) insulin were used most often, as these are more readily available in public hospitals (Table 1). The number of insulin injections per day increased over time ($p=0.01$) from 2.93 (95% CI 2.85 - 3.01) in P1 to 3.14 (95% CI 3.06 - 3.23) in P4 (Fig. 3). Most patients received 3 injections per day, i.e. 63 (87.5%) during P1 and 112 (81.8%) during P4. The number of patients managed on >4 insulin injections per day increased from two (2.8%) in P1 to 24 (17.5%) in P4, while the number treated with 2 insulin injections per day dropped from seven patients (9.7%) to one from P1 to P4, respectively.

In P1, the mean insulin dose was significantly higher ($p=0.00$) than in the other three periods (Fig. 4) for all patients. The dose dropped from a maximum of 1.19 (95% CI 1.08 - 1.31) units/kg/day in P1 to a minimum of 0.88 (95% CI 0.82 - 0.93) units/kg/day in P2. The dose was subsequently adjusted to 0.93 (95% CI 0.87 - 1.00) units/kg/day in P4.

Complications
The number of patients with documented complications over the four periods was small, but increased gradually as the number being screened increased (Table 2). This is presumably due to initial underdetection. For example, in P1 the presence of LJM was not assessed and only a single lipogram was requested. Complication detection improved when an aide-memoire was implemented in P2. Owing to low numbers, statistical analysis of complications was not possible, except for microalbuminuria and LDL cholesterol levels. The UAC was similar throughout all periods, i.e. 3.2 (95% CI 1.1 - 5.3), 3.4 (95% CI 0.3 - 6.5), 4.5 (95% CI 2.1 - 6.8) and 3.4 (95% CI 1.2 - 5.7) mg/mmol in P1, P2, P3 and P4, respectively. The LDL cholesterol level changed significantly from 3.4 (95% CI 3.0 - 3.8) mmol/L in P2 to 2.6 (95% CI 2.4 - 2.8) mmol/L in P3. LJM was shown not to be associated with HbA1c. Presence of retinopathy, all non-proliferative except for one case, was only documented in P3 and P4. Only one case of neuropathy was diagnosed (in P4).

Discussion
The improvement in HbA1c levels after the DCT had been introduced is encouraging. The increase in P2 was, however,
somewhat unexpected (Fig. 1). Resolution of the honeymoon period cannot account for this observation, because it would have occurred before the commencement of P2. However, in the unstudied period prior to P2, diabetes management was suboptimal because a full-time diabetes specialist was not available for the last 8 months and inexperienced staff were tasked with diabetes care. After a paediatric endocrinologist was reappointed and the DCT had been introduced, mean HbA1c levels improved again, with a total decrease of close to 2% being achieved.

In line with the recommendations of the DCCT, all patients were converted to a regimen of at least 3 injections per day. A significant drop in mean insulin dose, maintained over all periods, was observed. This drop may have been due to improved injection technique, therapy adherence and the introduction of a point-of-care HbA1c analyser, which facilitated immediate management discussions with the families. A similar decrease in HbA1c levels was achieved in another study when a primary nurse educator implemented DCCT recommendations, although the total daily dose had to be increased to achieve this effect. However, the effect of the DNE’s involvement may be hard to separate from that of changing to a multiple injection regimen. Maintaining the beneficial effect over the long term may be difficult: a 10-year study surveying the introduction of both a DCT and a multiple injection regimen at a higher dose showed no effect on median HbA1c levels.

Improved HbA1c levels reported in other studies after a DCT was introduced varied between 0% and 1.3%. However, these studies are not comparable to ours, for several reasons. Firstly, the time span in those studies was considerably shorter than in ours (i.e. 6 - 12 months v. 6 years). Secondly, most of those studies assessed the impact of a DCT or DNE on the glycaemic control of adults with type 2 diabetes, and this patient population is likely to respond differently to therapeutic interventions.

Thirdly, the combined effect of the reintroduction of specialist services, the appointment of a DNE and the standardisation of treatment to a multiple-dose injection regime resulted in a greater HbA1c decrease in our study. Lastly, institutionalisation of poorly controlled patients in our study may also have contributed to the observed results.

Despite the improvement, the attained glycaemic control is still far above the HbA1c target of 7.5% proposed by ISPAD. However, metabolic control is expected to continue to improve over time. The observation that the mean HbA1c levels were similar in P1 and P4 should not detract from the impact of introducing a DNE to the team. The marked difference in variability between the two periods may be attributed to the DNE’s effectiveness in reaching the group, as opposed to the restricted efforts of the paediatric endocrinologist alone.

In P4, 10 of the 11 girls (90.9%) and 7 of the 11 boys (63.6%) had reached puberty, a period known to be associated with poor glycaemic control. Insulin resistance and high insulin clearance usually necessitate a higher insulin dose. Adolescents are also well known to be resistant to change. Psychiatric disturbances, resulting in poor adherence and consequently poorer glycaemic control, are frequent. In a large study from Germany and Austria, median HbA1c levels in adolescents were found to be about 2% higher than in preschoolers. In contrast, in the present study, children (mostly adolescents) from predominantly poor socioeconomic backgrounds achieved improved glycaemic control with even less variation on a lower insulin dose.

A steady decline in the number of hospital admissions (about 75%) was seen over the study period. This pattern mirrors the change seen in HbA1c levels and translates to cost saving for the hospital. So far, studies assessing the effectiveness of a DCT have concentrated on documenting the reduced duration of hospitalisation. To our knowledge, only one study has previously assessed admission rates and found no effect on readmissions.

### Table 2. Prevalence of complications

<table>
<thead>
<tr>
<th>Complication</th>
<th>P1, n/N (%)</th>
<th>P2, n/N (%)</th>
<th>P3, n/N (%)</th>
<th>P4, n/N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microalbuminuria*</td>
<td>8/22 (36.4)</td>
<td>7/25 (28.0)</td>
<td>30/65 (46.2)</td>
<td>18/67 (26.9)</td>
</tr>
<tr>
<td>Retinopathy</td>
<td>0/25 (0.0)</td>
<td>0/34 (0.0)</td>
<td>6/45 (13.3)</td>
<td>6/58 (10.3)</td>
</tr>
<tr>
<td>Neuropathy</td>
<td>0/26 (0.0)</td>
<td>0/39 (0.0)</td>
<td>0/79 (0.0)</td>
<td>1/88 (1.1)</td>
</tr>
<tr>
<td>LJM†</td>
<td>-</td>
<td>13/50 (26.0)</td>
<td>36/89 (40.4)</td>
<td>42/98 (42.9)</td>
</tr>
<tr>
<td>High TSC‡</td>
<td>6/35 (17.1)</td>
<td>4/30 (13.3)</td>
<td>10/63 (15.9)</td>
<td>11/64 (17.2)</td>
</tr>
<tr>
<td>High LDLC§</td>
<td>1/1 (100)</td>
<td>4/19 (21.1)</td>
<td>5/61 (8.2)</td>
<td>5/42 (11.9)</td>
</tr>
<tr>
<td>Poor HDLC§</td>
<td>0/1 (0.0)</td>
<td>1/19 (5.3)</td>
<td>12/63 (19.0)</td>
<td>10/43 (23.3)</td>
</tr>
<tr>
<td>High TG</td>
<td></td>
<td></td>
<td>0/1 (0.0)</td>
<td>0/19 (0.0)</td>
</tr>
</tbody>
</table>


UAC = urine albumin–creatinine; LJM = limited joint mobility; TSC = total serum cholesterol; LDLC = low-density lipoprotein cholesterol; HDLC = high-density lipoprotein cholesterol; TG = triglycerides.

*Defined as UAC >2 mg/mmol in two consecutive early-morning urine samples.

†Not insulin treated.

‡>6.2 mmol/L.

§>4.1 mmol/L.

‡‡Boys: <1 mmol/L; Girls: <1.3 mmol/L.

||≤2.3 mmol/L.
The decreasing admission rate seen in the present study further attests to the effectiveness of a full DCT. Patients were mainly admitted because they developed DKA. As shown earlier, the DKA rate decreased in each period, affecting overall admission rates. The number of rDKA admissions also improved. A decrease in rDKA rate generally would not be expected, because children presenting with rDKA frequently have underlying social or behavioural pathology not amenable to intervention. However, a drop in the rDKA rate was probably achieved because patients were being institutionalised once the pathology had been detected. To our knowledge, such a reduction in DKA rates has not been demonstrated before.

Although HbA1c levels improved progressively over time, the prevalence of microalbuminuria did not change accordingly. Other studies suggest that a longer period of observation may be required for any effect on renal function to manifest. For example, it took 10 years before a 50% difference in nephropathy prevalence could be demonstrated in adult T1DM patients managed by diabetologists over those managed by generalists.[17] A similar reduction was achieved in paediatrics and adolescents 5 years after DCT institution and implementation of DCCT recommendations.[18,20]

Over time, LJM was more commonly recognised, with an actual prevalence of about 40%. In other studies, the reported prevalence of LJM ranges from 3.9% - 55%. This wide range probably relates to examination technique, the age of the population and the duration of diabetes.[20] As in other studies, an association between HbA1c levels and the occurrence of LJM could not be established.

Triglyceride levels remained constant during the assessed periods. A decrease in LDL cholesterol levels was seen in the short term, which probably reflects better glycaemic control. Similar changes, together with improved HDL cholesterol levels, were seen in another study following the introduction of a mobile DCT for adult type 2 diabetes patients.[23]

Circumstantial evidence suggests that many patients did not attend their ophthalmology appointments before the introduction of fundal photography in P4, which may explain why no retinopathy was identified during the first two periods. The actual prevalence may therefore be higher than what was observed. Presumably this is also true for neuropathy, as only one patient was identified after four periods. Inadequate screening is not unique to this service. Both adult and paediatric literature suggest that the prevalence of these two complications is 12% at best,[8,14,15] i.e. considerably higher than what was observed in the current study. Efforts to detect all possible complications therefore need to be intensified. Furthermore, a prospective study would be more effective in detecting complications.

The limitations alluded to here are typical of any retrospective study. For example, some patients may have escaped repeat testing for microalbuminuria, which may have artificially inflated the microalbuminuria rate and could consequently have been interpreted as a lack of improvement. Data on the duration of the honeymoon period or the duration of illness, puberty and body mass index, all of which could have affected glycaemic control, were not collected. However, a significant improvement in HbA1c levels was seen over time, suggesting that these factors were fairly inconsequential. As about a quarter of our patient population resides in rural areas, patients who had developed DKA could have presented at peripheral hospitals, resulting in under-reporting of the DKA rate at our centre. This bias should, however, be fairly constant across all periods.

Conclusion

A significant improvement in glycaemic control of paediatric and adolescent T1DM patients from a lower socioeconomic background was achieved in a resource-poor environment by re-establishing specialist care and introducing a full DCT. Switching all patients to a multiple-dose injection regimen probably contributed to the improvement. Low variation in HbA1c levels was achieved in predominantly pubertal patients at a lower daily insulin dose.

The effect of improved metabolic control was monitored by a reduction in admission and DKA rates over time, confirming the value of the DCT in the management of T1DM patients.

Declaration. This manuscript was submitted in partial fulfilment of the requirements for the degree of Master of Medicine.

Acknowledgements. The authors kindly acknowledge S. Zöllner for language support, Dr M.A. van Rensburg, Tygerberg Hospital, for chemical pathology support and the DNEs at Tygerberg Hospital who provided some of the data.

Author contributions. As the principal investigator, ZK performed the study, collected and summarised all the data, assisted with interpretation of data and wrote the manuscript. JH analysed data and assisted with interpretation, and wrote the section on statistical analysis. EZ contributed substantially to the conception and design of the study, interpretation of the data and preparing the manuscript.

Funding. None.

Conflicts of interest. None.

References


Accepted 23 August 2018.